Artificial intelligence cardiac imaging providers target underserved congenital heart disease (CHD) patient population

VentriPoint Diagnostics (TSXV: VPT; OTC: VPTDF) has launched a targeted marketing program for congenital heart defects (CHD) that uses its AI-enhanced VMS+ echocardiography technology to provide cardiac analysis comparable to MRI using standard ultrasound devices. The program aims to address the barriers to accessibility to lifelong surveillance in patients with congenital heart disease (CHD), while laying the foundation for expanding the diagnosis of cardiac tumors, pulmonary hypertension, heart failure and valve disease.